Skip to main content

Drug Interactions between momelotinib and sirolimus protein-bound

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sirolimus protein-bound momelotinib

Applies to: sirolimus protein-bound and momelotinib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of momelotinib may increase the plasma concentrations and effects of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. The proposed mechanism is increased exposure of the P-gp substrate due to inhibition of intestinal P-gp efflux transporter. However, clinical data are not available.

MANAGEMENT: Caution is recommended with the concomitant use of momelotinib and P-gp substrates, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever momelotinib is added to or withdrawn from therapy with these drugs. Individual product labeling for the coadministered drug may also be consulted for specific guidance.

Drug and food/lifestyle interactions

Moderate

sirolimus protein-bound food/lifestyle

Applies to: sirolimus protein-bound

Grapefruit juice may increase the blood levels of sirolimus protein-bound. However, this has not been studied, and it is not known to what extent grapefruit juice may interact with sirolimus protein-bound. High blood levels of sirolimus protein-bound can increase side effects such as mouth sores and inflammation, nausea, diarrhea, vomiting, abdominal pain, decreased appetite, increased blood sugar, rash, hair loss, lung or breathing problems, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. The manufacturer recommends avoiding grapefruit and grapefruit juice during treatment with sirolimus protein-bound. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.